Novartis (NVS) Stock Price, Quote, News & History | Benzinga

SPY761.10−1.39%QQQ707.87−2.77%BTC/USD81,385.30−0.14%DIA518.00−0.59%GLD381.40−0.34%TLT80.06+0.11%

Novartis AG (NVS) Stock Price, Quote, News & History

NVSNYSE

Trade with Public

Trade with Public

$150.60

0.220.15%

Last update: Oct 16, 6:38 PM

$148.40

-1.98-1.32%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Dividends Compare Options Stock Report

Key Statistics

Open

$150.65

Close

$150.60

Volume / Avg.

1.73M / 1.96M

Day Range

$148.40 - $148.40

52 Wk Range

121.57 - 170.46

Market Cap

$279.18B

P/E Ratio

22.72

Dividend Yield

3.15%

Exchange

NYSE

RSI

51

Short Interest

0.3%

Days to Cover

2.93

Recent Novartis AG News

FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives

FDA approves Novartis’s Rhapsido for symptomatic dermographism, marking the first treatment for adults with friction-triggered chronic hives

Vandana Singh

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.

Vandana Singh

Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform

Novartis halted its mid-stage ALS drug trial for VHB937 but exercised a $125 million option to acquire Sironax's brain delivery platform.

Vandana Singh

Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks

Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sharp stock declines after trial setbacks.

Vandana Singh

Nvidia, FAA Join Palantir’s AI Expansion as Cyber Push Takes Off

Palantir expands its AI footprint via new enterprise deployments, a free cybersecurity initiative, and an upgraded sovereign AI partnership with Fujitsu.

Anusuya Lahiri

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

18.39B

Investing Cash Flow (TTM)

-17.81B

Financing Cash Flow (TTM)

453.00M

Free Cash Flow (TTM)

14.98B

Capital Expenditure (TTM)

-3.41B

Net Change in Cash (TTM)

1.04B

Analyst Trends and Forecast

0

0

0

0

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.5

Sell

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$329.01B

PE Ratio (TTM)

22.72

PE Ratio (FWD)

15.50

PEG Ratio (TTM)

3.52

PS Ratio (TTM)

5.11

PB Ratio (TTM)

6.88

Earnings Yield % (TTM)

4.40%

Earnings Yield % (FWD)

6.45%

EV / EBITDA (TTM)

14.65

Price / EBITDA (TTM)

12.91

Price / Free Cash Flow (TTM)

19.35

Book Value / Share

$21.86

Company Debt

Total Debt

$47.08B

LT Debt

$37.49B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$286.00M

Total Cash

$7.62B

Debt to Equity

1.18

Issuance of Debt (TTM)

$18.71B

Repayment of Debt (TTM)

-$2.10B